Scientific Publications

Legend Biotech sponsors research with academic institutions to evaluate our agents. The manuscripts from this research are presented below.

Year :

Five‑year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR‑B38M chimeric antigen receptor T cells in the LEGEND‑2 study: a case report

BY Wang, WH Zhao, YX Chen, XM Cao, Y Yang, YL Zhang, FX Wang, PY Zhang, B Lei, LF Gu, JL Wang, J Bai, Y Xu, XG Wang, RL Zhang, LL Wei, QC Zhuang, F Fan, WG Zhang, AL He, J Liu

Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice

Delforge M, Vekemans M, Depaus J, Meuleman N, Van De Velde A, Van De Broeck I, S Vandervennet, S V Hoorenbeeck, E Moorkens, Strens D, J Diels, F Ghilotti, Haefliger B, S Dalhuisen, W Deraedt, Anguille S

Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma

Tom Martin, Saad Z. Usmani, Jordan M. Schecter, Tito Roccia, Carolyn C. Jackson, William Deraedt, Tzu-min Yeh, Arnob Banerjee, Lida Pacaud, Ashraf Garrett, Meaghan Bartlett, Anja Haltner, Suzy Van Sanden, Joris Diels, Satish Valluri & Imtiaz A. Samjoo

Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study

Adam D. Cohen, Parameswaran Hari, Myo Htut, Jesus G. Berdeja, Saad Z. Usmani, Deepu Madduri, Yunsi Olyslager, Jenna D. Goldberg, Jordan M. Schecter, Carolyn C. Jackson, Katharine S. Gries, John M. Fastenau, Satish Valluri, William Deraedt, Muhammad Akram, Rebecca Crawford, Ross Morrison, Lynda Doward, Kate Morgan, Silene ten Seldam, Andrzej Jakubowiak, Sundar Jagannath

Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor–T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)

Mi JQ, Zhao W, Jing H, Fu W, Hu J, Chen L, Zhang Y, Yao D, Chen D, Schecter JM, Yang F, Tian X, Sun H, Zhuang SH, Ren J, Fan X, Jin J, Niu T, Chen SJ